1382 DKK1 is a biomarker and immunotherapeutic target for bone metastases in malignant cancers

Tao Shi, Kaijie Liang, Xiaoyu Zhou, Xueru Song, Hanbing Wang, Yipeng Zhang, Lixia Yu, Baorui Liu, Wei JiaRegular 2022 · DOI

Abstract

Malignant tumors with bone metastases represent a significant clinical challenge, often resulting in poor prognosis and limited therapeutic options. This study investigates the role of Dickkopf-1 (DKK1) as both a diagnostic biomarker and a therapeutic target. By analyzing serum samples from gastric cancer (GC) patients and utilizing preclinical mouse models, researchers demonstrated that DKK1 levels correlate with disease progression and bone involvement. Furthermore, pharmacological blockade of DKK1 using the antibody mDKN-01 was found to reduce tumor burden, alleviate bone destruction, and reprogram the bone-tumor immune microenvironment (bone-TIME) toward a pro-inflammatory, anti-tumor state. These findings suggest that DKK1 is a promising candidate for targeted immunotherapy in patients with skeletal malignancies.

Introduction

Bone metastasis is a devastating complication of advanced cancer, significantly impacting patient survival and quality of life through skeletal-related events such as severe pain and pathological fractures. The bone microenvironment is a complex "soil" where tumor cells hijack physiological bone remodeling to create a protective, immunosuppressive niche. Despite its clinical importance, the bone-tumor immune microenvironment (bone-TIME) remains poorly understood, and effective therapies specifically targeting bone-localized disease are lacking.

Dickkopf-1 (DKK1) is a known inhibitor of the Wnt signaling pathway, which is essential for bone formation. This study explores whether DKK1 serves as a critical link between tumor progression and bone-TIME modulation, potentially offering a new avenue for both prediction and treatment.

Methods

Clinical Analysis

To evaluate the clinical relevance of DKK1, researchers measured serum DKK1 levels in 63 gastric cancer (GC) patients and 25 healthy donors. The GC cohort was stratified by disease stage (Stage II-III vs. Stage IV) and treatment response (Progressive Disease [PD] vs. Complete/Partial Response [CR/PR]).

Preclinical Modeling and Treatment

Bone metastasis models were established in mice using an intra-caudal artery (CA) injection of gastric and breast cancer cells. This method specifically targets the bone marrow of the hind limbs, providing a more physiologically relevant model of skeletal spread than standard systemic injections. The therapeutic efficacy of DKK1 blockade was tested using mDKN-01, a murine version of a clinical-stage DKK1-blocking antibody.

Analytical Modalities

Tumor burden and bone integrity were assessed using micro-CT, MRI, and immunohistochemical (IHC) staining. The bone-TIME was characterized via flow cytometry and immunofluorescence to quantify changes in immune cell populations, including T cells, macrophages, and dendritic cells.

Results

DKK1 as a Biomarker for Bone Metastasis

Clinical data revealed a significant correlation between DKK1 levels and disease severity. Serum DKK1 was elevated in GC patients compared to healthy controls, with the highest concentrations observed in Stage IV patients—particularly those with confirmed bone metastases (n=22). Furthermore, DKK1 levels proved to be dynamic indicators of treatment response: levels increased in patients with progressive disease and decreased in those achieving a complete or partial response.

Therapeutic Impact on Tumor Burden and Bone Health

In mouse models of both gastric and breast cancer bone metastasis, treatment with mDKN-01 significantly reduced tumor burden. Micro-CT imaging demonstrated that DKK1 blockade inhibited osteoclast activation, thereby alleviating the bone destruction typically associated with metastatic infiltration. This suggests that DKK1 inhibition can effectively break the "vicious cycle" of bone resorption and tumor growth.

Reprogramming the Bone-Tumor Immune Microenvironment

One of the study's most significant findings was the shift in the immunological landscape of the bone marrow. DKK1 blockade transformed the bone-TIME from an immunosuppressive environment to an active, anti-tumor state. Key changes included:

  • Increased CD8+ T cells: Enhancement of the primary effector cells responsible for killing tumor cells.
  • M1-like Macrophage Polarization: A shift toward pro-inflammatory macrophages that promote tumor attack, rather than M2-like macrophages that support tumor growth.
  • Dendritic Cell Activation: Increased proportions of activated dendritic cells (DCs), which are essential for priming the adaptive immune response.

Discussion and Conclusion

This research identifies DKK1 as a "double threat" in the context of bone metastasis. Clinically, it serves as a robust biomarker for identifying patients at high risk for skeletal spread and monitoring their response to therapy. Therapeutically, DKK1 blockade not only preserves bone structural integrity by inhibiting osteoclasts but also "flips" the immune switch within the bone marrow, recruiting and activating the body's own defenses against the tumor.

While further research is needed to clarify the precise molecular pathways linking DKK1 inhibition to dendritic cell activation, these results provide a strong rationale for the clinical development of DKK1-targeted therapies. By improving the bone-TIME, DKK1 inhibitors like DKN-01 could become a cornerstone of treatment for patients with bone-metastatic cancers, potentially in combination with existing checkpoint inhibitors or standard-of-care chemotherapies.

Summary updated

Abstract

<h3>Background</h3> Malignant tumors with bone metastases seriously threaten the survival of cancer patients. However, the understanding of bone-tumor microenvironment remains poor, and currently, there is no effective therapeutic target for bone metastases. <h3>Methods</h3> Serum Dickkopf-1 (DKK1) expression from healthy donors and gastric cancer (GC) patients were detected. Mouse GC and breast cancer bone metastasis model was established by intro-caudal artery (CA) GC cell injection, and <i>in vivo</i> efficacy of DKK1 blockade with murine DKK1 antibody (mDKN-01) was evaluated by micro-CT, MRI and IHC staining modalities. The bone-tumor immune microenvironment (bone-TIME) was analyzed via flow cytometry and immunofluorescence. <h3>Results</h3> Serum DKK1 expressions were increased in GC patients (n=63) than in healthy donors (n=25), and stage IV GC patients (n=42) had higher serum DKK1 levels than stage II-III patients (n=21), with bone-metastatic patients (n=22) displaying the highest DKK1 level. Also, serum DKK1 levels are increased in patients with progressive disease (PD), while decreased in patients who had complete response (CR)/partial response (PR) to treatments. DKK1 blockade by mDKN-01 obviously reduced the tumor burden of bone metastases, and significantly inhibited osteoclast activation and alleviates bone destruction in different bone metastasis models. Moreover, the bone-TIME was improved after DKK1 blockade, with increased proportions of CD8<sup>+</sup> T cells, M1-like macrophages, and activated dendritic cells (DCs). <h3>Conclusions</h3> Our study suggests DKK1 as a potential predictor to bone metastasis and progressive disease in cancer patients. Blockade of DKK1 brings an improved bone-TIME, therefore, DKK1 could be considered as a novel and promising immunotherapeutic target for bone metastases.
BibTeX
@inproceedings{shi2022dkk,
  author = {Tao Shi and Kaijie Liang and Xiaoyu Zhou and Xueru Song and Hanbing Wang and Yipeng Zhang and Lixia Yu and Baorui Liu and Wei Jia},
  title = {{1382 DKK1 is a biomarker and immunotherapeutic target for bone metastases in malignant cancers}},
  booktitle = {Regular},
  year = {2022},
  doi = {10.1136/jitc-2022-sitc2022.1382},
}
Figure